Abstract
Nicotinic acid receptor mutations have been associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) [ [1] Chen Y. Wu L. Fang Y. et al. A novel mutation of the nicotinic acetylcholine receptor gene CHRNA4 in sporadic nocturnal frontal lobe epilepsy. Epilepsy Res. 2009; 83: 152-156 Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar ]. Nicotine and more specifically transdermal nicotine patches (NP) have been used as adjunctive treatments for ADNFLE [ 2 Brodtkorb E. Picard F. Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy. Epilepsy Behav. 2006; 9: 515-520 Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar , 3 Willoughby J.O. Pope K.J. Eaton V. Nicotine as an antiepileptic agent in ADNFLE: an N-of-one study. Epilepsia. 2003; 44: 1238-1240 Crossref PubMed Scopus (56) Google Scholar , 4 Schoenfeld J. Sotero De Menezes M. Nicotine patch for the treatment of intractable ADNFLE in a non-smoking pediatric patient. http://www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/sotero/sy/2010/sb/All/id/12832 Google Scholar ]. The translation of nicotine supplements into potential adjunctive treatments for a broader group of patients without ADNFLE has not been investigated. As far as we are aware, no data suggest that nicotine use diminishes seizure frequency in any population besides those with frontal lobe epilepsies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
